TrialPath
Recruiting

REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)

NCT05665556 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE) at the National Institute of Medical Sciences and Nutrition Salvador Zubirán
About this study
Connective tissue diseases represents an important risk factor for pulmonary hypertension, either due to vasculopathy or chronic pulmonary thromboembolism. These chronic conditions are characterized by being disabling, progressive and fatal in a short time and are caused by multiple mechanisms that results in remodeling of the pulmonary microvasculature and right heart failure. In recent years, due to international registries, we have acquired a better understanding of high-risk subpopulations, their poor prognostic factors, and the results of specific combination therapies. In Mexico, the National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ) is a referral center for connective tissue diseases and pathologies of the pulmonary circulation. The RECONNECTIVE registry is a five years follow-up cohort that offers the possibility to obtain data regarding to the clinical characteristics and hemodynamic assesment of pulmonary circulation. The main objective is to evaluate the clinical course of the PAH in this subgroup of patients and their specific therapy for PAH.
Eligibility criteria
Inclusion Criteria: * Incident and prevalent patients diagnosed with Group I associated with Connective Tissue Diseases (CTD) * Incident and prevalent patients diagnosed with Group IV Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) with evidence of a chronic thromboembolic pulmonary disease by ventilation/perfusion pulmonary gammagraph or computed tomography pulmonary angiogram with at least three months of total anticoagulation therapy. * Patient diagnosed with a connective tissue disease according to the classification criteria of the American College of Rheumatology. * Precapillary pulmonary hypertension confirmed by right heart catheterization (RHC): Mean pulmonary arterial pressure (mPAP) \>20 mm Hg with a pulmonary arterial wedge pressure ≤ 15 mm Hg and Pulmonary vascular resistance (PVR) ≥ 2.0 Wood units Exclusion Criteria: * Patients who meet the criteria for another group of pulmonary hypertension (Groups II, III or V).
Study design
Enrollment target: 170 participants
Age groups: adult, older_adult
Timeline
Starts: 2022-12-15
Estimated completion: 2027-12
Last updated: 2023-06-29
Primary outcomes
  • To characterize the clinical clinical course of Pulmonary Arterial Hypertension (PAH) associated with Connective Tissue Diseases (CTD) in a register of Mexican patients from the first visit and at every 6 months. (5 years)
Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · other
Contacts & investigators
ContactJose Luis Hernandez Oropeza, PhD · contact · elinternista@hotmail.com · +52 55 5487 0900
ContactJose de Jesus Rodriguez Andoney, M.Sc. · contact · andoneyjjr@hotmail.com · +52 55 5487 0900
InvestigatorJose Luis Hernandez Oropeza, PhD · principal_investigator, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
All locations (1)
Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránRecruiting
Mexico City, Mexico
REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE) · TrialPath